MA47015B1 - Conjugués oligomères de sauts d'exons pour la dystrophie musculaire - Google Patents

Conjugués oligomères de sauts d'exons pour la dystrophie musculaire

Info

Publication number
MA47015B1
MA47015B1 MA47015A MA47015A MA47015B1 MA 47015 B1 MA47015 B1 MA 47015B1 MA 47015 A MA47015 A MA 47015A MA 47015 A MA47015 A MA 47015A MA 47015 B1 MA47015 B1 MA 47015B1
Authority
MA
Morocco
Prior art keywords
oligomer conjugates
muscular dystrophy
exon skipping
skipping oligomer
exon
Prior art date
Application number
MA47015A
Other languages
English (en)
Other versions
MA47015A (fr
Inventor
Marco Passini
Gunnar Hanson
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Priority claimed from PCT/US2017/066351 external-priority patent/WO2018118627A1/fr
Publication of MA47015A publication Critical patent/MA47015A/fr
Publication of MA47015B1 publication Critical patent/MA47015B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des conjugués oligomère antisens capables de se lier à un site cible sélectionné du gène de la dystrophine humaine pour induire le saut de l'exon 45 sont décrites.
MA47015A 2016-12-19 2017-12-14 Conjugués oligomères de sauts d'exons pour la dystrophie musculaire MA47015B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436199P 2016-12-19 2016-12-19
PCT/US2017/066351 WO2018118627A1 (fr) 2016-12-19 2017-12-14 Conjugués oligomères de sauts d'exons pour la dystrophie musculaire

Publications (2)

Publication Number Publication Date
MA47015A MA47015A (fr) 2019-10-23
MA47015B1 true MA47015B1 (fr) 2022-11-30

Family

ID=66326249

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47015A MA47015B1 (fr) 2016-12-19 2017-12-14 Conjugués oligomères de sauts d'exons pour la dystrophie musculaire

Country Status (2)

Country Link
AR (1) AR110537A1 (fr)
MA (1) MA47015B1 (fr)

Also Published As

Publication number Publication date
AR110537A1 (es) 2019-04-10
MA47015A (fr) 2019-10-23

Similar Documents

Publication Publication Date Title
MA65895B1 (fr) Conjugués d'oligomères induisant le saut d'exons pour la dystrophie musculaire
MA45618A (fr) Sauts d'exons oligomères pour la dystrophie musculaire
MX2019006882A (es) Conjugados de oligomeros de omision de exon para distrofia muscular.
EA202090744A1 (ru) Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
MY205772A (en) Exon skipping oligomer conjugates for muscular dystrophy
CY1121876T1 (el) Συνθεσεις παρακαμψης εξωνιου για τη θεραπεια της μυϊκης δυστροφiας
IL268856A (en) Methods for purification of messenger rna
IL271389A (en) Targeted non-viral dna insertions
CY1123119T1 (el) Αντινοηματικο νουκλεϊκο οξυ
MA49913A (fr) Variants d'arn polymérase
EP3463483A4 (fr) Traitement de dyskinésie ciliaire primaire à l'aide d'arn messager de synthèse
EP3463290A4 (fr) Régulation à contre-réaction du vih-1 par une stratégie d'édition génique
WO2019241385A3 (fr) Oligomères induisant un saut d'exon pour la dystrophie musculaire
EA202092772A1 (ru) Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
EP3347098A4 (fr) Ciblage de l'activation de mda-5 pour l'immunothérapie du cancer
EP3347466A4 (fr) Détermination du nombre de copies génétiques au moyen d'un séquençage multiplex à haut débit de nucléotides smash
EP3344650A4 (fr) Aav-epo pour le traitement d'animaux de compagnie
EP3673505A4 (fr) Ensemble d'injection pour des processus de dépôt épitaxial
EP3367784A4 (fr) Ingénierie d'organes humanisés par complémentation génétique
EA202191601A1 (ru) Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
EP3693487A4 (fr) Acier inoxydable à base d'austénite
MA47015B1 (fr) Conjugués oligomères de sauts d'exons pour la dystrophie musculaire
MA51582B1 (fr) Conjugués oligomères de sauts d'exons pour la dystrophie musculaire
MA51587B1 (fr) Conjugués oligomère de sauts d'exons pour la dystrophie musculaire
EP3363464A4 (fr) Composition pharmaceutique pour le traitement du cancer comprenant un oligonucléotide d'arn